Belaydi Othmane

1.0k total citations · 1 hit paper
17 papers, 545 citations indexed

About

Belaydi Othmane is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Belaydi Othmane has authored 17 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Belaydi Othmane's work include Bladder and Urothelial Cancer Treatments (11 papers), Ferroptosis and cancer prognosis (8 papers) and RNA modifications and cancer (4 papers). Belaydi Othmane is often cited by papers focused on Bladder and Urothelial Cancer Treatments (11 papers), Ferroptosis and cancer prognosis (8 papers) and RNA modifications and cancer (4 papers). Belaydi Othmane collaborates with scholars based in China, United States and Germany. Belaydi Othmane's co-authors include Jinbo Chen, Jiao Hu, Xiongbing Zu, Huihuang Li, Anze Yu, Wenbiao Ren, Peihua Liu, Dongxu Qiu, Guanghui Gong and Minfeng Chen and has published in prestigious journals such as Frontiers in Immunology, BMC Medicine and Theranostics.

In The Last Decade

Belaydi Othmane

17 papers receiving 541 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

2021 250 citations Jiao Hu, Anze Yu et al. Theranostics profile →

Peers

Belaydi Othmane

PRM

ONCOL

SURGE

Silvia de Muga Spain

Ziyang Liu China

Mingjiong Zhang China

Charlotta Hedner Sweden

Lynda Vuong United States

Yan Mao China

Baobao Cai China

Muhammad Zubair Afzal United States

Sishun Gan China

Rico D. Bense Netherlands

Silvia de Muga Spain

Belaydi Othmane

264 ×0.9

201 ×0.8

PRM

149 ×0.9

112 ×0.6

ONCOL

124 ×0.8

SURGE

Citations per year, relative to Belaydi Othmane Belaydi Othmane (= 1×) peers Silvia de Muga

Countries citing papers authored by Belaydi Othmane

Since Specialization

Citations

This map shows the geographic impact of Belaydi Othmane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Belaydi Othmane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Belaydi Othmane more than expected).

Fields of papers citing papers by Belaydi Othmane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Belaydi Othmane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Belaydi Othmane. The network helps show where Belaydi Othmane may publish in the future.

Co-authorship network of co-authors of Belaydi Othmane

This figure shows the co-authorship network connecting the top 25 collaborators of Belaydi Othmane. A scholar is included among the top collaborators of Belaydi Othmane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Belaydi Othmane. Belaydi Othmane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Zhao, Xu, et al.. (2023). LncRNA AGAP2-AS1 interacts with IGF2BP2 to promote bladder cancer progression via regulating LRG1 mRNA stability. Cellular Signalling. 111. 110839–110839. 12 indexed citations

Othmane, Belaydi, et al.. (2022). Filling the gaps in the research about second primary malignancies after bladder cancer: Focus on race and histology. Frontiers in Public Health. 10. 1036722–1036722. 1 indexed citations

Liu, Peihua, Belaydi Othmane, Jiao Hu, et al.. (2022). m⁶A-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism. Theranostics. 12(14). 6291–6307. 51 indexed citations

Yi, Zhenglin, Zhenyu Ou, Jiao Hu, et al.. (2022). Computer-aided diagnosis of prostate cancer based on deep neural networks from multi-parametric magnetic resonance imaging. Frontiers in Physiology. 13. 918381–918381. 9 indexed citations

Hu, Jiao, Lan Gu, Jinbo Chen, et al.. (2022). THEM6: A Novel Molecular Biomarker Predicts Tumor Microenvironment, Molecular Subtype, and Prognosis in Bladder Cancer. Disease Markers. 2022. 1–28. 3 indexed citations

Hu, Jiao, Belaydi Othmane, Anze Yu, et al.. (2021). 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. BMC Medicine. 19(1). 289–289. 52 indexed citations

Yi, Zhenglin, Zhenyu Ou, Xi Guo, et al.. (2021). Recurrence factors in patients with Keratinizing squamous metaplasia of the bladder after surgical management: a single-center retrospective study. Translational Andrology and Urology. 10(2). 734–740. 3 indexed citations

Luo, Cong, Wenrui Ye, Jiao Hu, et al.. (2021). A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer. Frontiers in Oncology. 11. 660273–660273. 10 indexed citations

Li, Huihuang, Jiao Hu, Anze Yu, et al.. (2021). RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology. 11. 642159–642159. 27 indexed citations

10.

Quan, Chao, Belaydi Othmane, Jiao Hu, et al.. (2021). N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target. Frontiers in Immunology. 12. 697026–697026. 20 indexed citations

11.

Zhang, Chunyu, Jiao Hu, Huihuang Li, et al.. (2021). Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis. Frontiers in Oncology. 11. 648968–648968. 15 indexed citations

12.

Guo, Tao, Jinbo Chen, Jinhui Liu, et al.. (2021). N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology. 11. 718644–718644. 18 indexed citations

13.

Liu, Zhi, Qiao Tang, Belaydi Othmane, et al.. (2021). A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. Frontiers in Immunology. 12. 725223–725223. 27 indexed citations

14.

Hu, Jiao, Anze Yu, Belaydi Othmane, et al.. (2021). Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 11(7). 3089–3108. 250 indexed citations breakdown →

15.

Qiu, Dongxu, Junwen M. Hu, Jiao Hu, et al.. (2021). PMEPA1 Is a Prognostic Biomarker That Correlates With Cell Malignancy and the Tumor Microenvironment in Bladder Cancer. Frontiers in Immunology. 12. 705086–705086. 16 indexed citations

16.

Cai, Zhiyong, Jiao Hu, Belaydi Othmane, et al.. (2021). Effects of Fibrin Clot Inhibitors and Statins on the Intravesical Bacille Calmette–Guérin Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 11. 614041–614041. 3 indexed citations

17.

Liu, Zhi, Xiaowen Li, Belaydi Othmane, et al.. (2021). A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer. Frontiers in Immunology. 12. 791924–791924. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact